Enovis Corporation (NYSE:ENOV) is one of the best medical device stocks to buy according to analysts. On August 8, UBS lowered the firm’s price target on Enovis Corporation (NYSE:ENOV) to $57 from $65, keeping a Buy rating on the shares.
A patient recieving cold therapy treatment using the company's products.
The rating update came after Enovis Corporation (NYSE:ENOV) reported fiscal Q2 2025 earnings on August 7, with net sales for the quarter reaching $565 million, reflecting a 7% growth on a reported basis and 5% on an organic basis compared to the same quarter last year.
Management reported that fiscal Q2 results reflect stable end markets, continued execution in P&R and Recon, and positive momentum in new product introductions.
Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments.
While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
